Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads In Thrombosis
Thrombosis for January/February 2019
TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885
Thrombosis for November/December 2018
Apixaban tied to lower VTE rate, higher bleeding risk in cancer, Carrier M et al. N Engl J Med. 2018 Dec 4. doi: 10.1056/NEJMoa1814468
Emapalumab for primary hemophagocytic lymphohistiocytosis, Locatelli F et al. ASH 2018; Abstract LBA-6
Apixaban surpasses DOACs in very elderly patients, Deitelzweig SB et al. Circulation. 2018 Nov 6;138[suppl 1]:A14900
Similar VTE rates seen with tofacitinib, TNF inhibitors, Desai RJ et al. Arthritis Rheumatol. 2018;70(suppl 10), Abstract L09
Recurrence risk high regardless of VTE classification, Albertsen IE et al. Am J Med. 2018 Sep;131(9):1067-74.e4
Thrombosis for September/October 2018
Genetic key to bleeding risk with warfarin, Perera MA et al. JAMA. 2018 Oct 23. doi: 10.1001/jama.2018.14955
Complications in EPOCH-R versus R-CHOP, David RJ et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 29. doi: 10.1016/j.clml.2018.08.014
Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30
Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919
DOACs perform well in real-world AF study, ESC CONGRESS 2018
Thrombosis for July/August 2018
CBC outperforms D-dimer in predicting DVT, The annual meeting of the American College of Physicians
Large cohort study demonstrates DOAC safety vs. warfarin , Vinogradova Y et al. BMJ 2018;362:k2505.